Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.
Cartiva has raised $6 million from a single investor to back its musculoskeletal foot surgical products just ahead of its first PMA review. The financing could be expanded to up to $8.5 million, according to an SEC filing. The startup has previously identified New Enterprise Associates, which has a partner on its board, as its primary investor.
Stryker announced FDA clearance to use the Mako robotic surgery system for total hip replacement, as well as the launch of a new bone matrix, and spine-stabilizing cervical plate at the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas.
Johnson & Johnson's DePuy Synthes unit struck a deal with medical imaging outfit Radlink to pair the company's real-time imaging technology with its hip replacement products, increasing its orthopedics clout as it looks to chart growth in the field.
Semma Therapeutics aims to provide beta cells--the pancreatic cells that produce insulin--to patients with Type 1 diabetes. If the startup can get beyond early research, an implantable device that creates insulin via these stem cell-derived beta cells could replace daily insulin injections and transform patient care.
St. Jude Medical's transcatheter aortic valve replacement, or TAVR, cardiology device is now commercially available in Europe once again, after its CE mark was suspended following safety concerns about reduced valve leaflet mobility arising from the company's U.S. clinical trials.
Sunshine Heart has temporarily suspended the clinical trial of its C-Pulse Heart assist system after four patients died during the trial, but says that the deaths were not related to the device.
Cyfuse Biomedical is aiming to take its 3-D bioprinting technology to researchers around the world with its infusion of ¥1.4 billion ($12 million). Its bioprinter can be used to create tissue structures including cartilage and subchondral bone, tubular tissues such as blood vessels, digestive and urinary organs, and miniature livers.
Teijin and Nakashima Holdings are joining forces to try to claim a bigger share of the Japanese medical device market. Teijin is acquiring half of Nakashima Medical, a subsidiary of Nakashima Holdings, for about ¥1.5 billion ($12.6 million) as of April 1.
In mid-January, Johnson & Johnson asked the district judge overseeing the federal lawsuit over the transvaginal mesh devices from its Ethicon subsidiary to investigate phone calls urging women with the implant to file suit against the company. But now it's requesting to withdraw that motion.